Sickle Cell Disease Patients‘ Views on Oxbryta

OXBRYTA (voxelotor) is a prescription medicine used for the treatment of sickle cell disease (SCD) and constitutes the first aproved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.

Oxbryta is already being used in the US for the treatment of SCD in adults and children 12 years of age and older, whilst it is still pending approval in the EU by the European Medicines Agency (EMA).

TIF conducted both a brief online survey between 16-26 February 2021 and an online consultation on 18 February 2021 to collect feedback from SCD patients regarding Oxbryta. The survey results and a summary of the patients‘ views are demonstrated below.

This survey has been completed!

Survey Results

Schaltfläche "Zurück zum Anfang"